Technologies to address antimicrobial resistance

Proceedings of the National Academy of Sciences of the United States of America

Volumn 115, Issue 51, 2018, Pages 12887-12895

  Baker, Stephen J ^a   Payne, David J ^a   Rappuoli, Rino ^b   De Gregorio, Ennio ^b  

^a GLAXOSMITHKLINE   (United States)

^b GSK   (Italy)

Author keywords

AMR; Antibiotics; Bacterial infections; Vaccines

Indexed keywords

CEFIDEROCOL; COLISTIN; FLAGELLIN; LISINOPRIL; METRONIDAZOLE; MONOCLONAL ANTIBODY; OLIGONUCLEOTIDE; PIPERACILLIN PLUS TAZOBACTAM; POLYSACCHARIDE; RECOMBINANT DNA; ROSUVASTATIN; VANCOMYCIN; XENOBIOTIC AGENT; ANTIINFECTIVE AGENT; BACTERIAL VACCINE;

ACINETOBACTER; ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; CONJUGATION; DOWN REGULATION; DRUG METABOLISM; GENOMICS; GLYCOCONJUGATION; HAEMOPHILUS INFLUENZAE; HERPES ZOSTER; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; HYDROLYSIS; IN VIVO STUDY; KLEBSIELLA; KLEBSIELLA PNEUMONIAE; MEDICAL RESEARCH; MEMBRANE VESICLE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOME; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MYCOBACTERIUM TUBERCULOSIS; NEISSERIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTER MEMBRANE VESICLE; PATHOGENIC ESCHERICHIA COLI; PEPTOCLOSTRIDIUM DIFFICILE; PERSONALIZED MEDICINE; PHAGE THERAPY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; RISK FACTOR; SALMONELLA ENTERICA SEROVAR TYPHI; SHIGELLA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TOXICITY TESTING; UPREGULATION; VACCINATION; BACTERIAL INFECTION; BACTERIUM; DRUG DELIVERY SYSTEM; DRUG EFFECT; HEALTH SERVICE; IMMUNOLOGY; TRENDS;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; BACTERIAL VACCINES; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, BACTERIAL; HUMANS; MEDICAL OVERUSE;

EID: 85058674254     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1717160115     Document Type: Review

References (48)

1. Centers for Disease Control and Prevention (2013) Antibiotic resistance threats in the United States, 2013. Available at https://www.cdc.gov/drugresistance/threat-report-2013/index.html. Accessed August 1, 2018.
2. Rhomberg PR, Jones RN (2009) Summary trends for the meropenem yearly susceptibility test information collection program: A 10-year experience in the United States (1999-2008). Diagn Microbiol Infect Dis 65:414–426.
3. Liu Y-Y, et al. (2016) Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: A microbiological and molecular biological study. Lancet Infect Dis 16:161–168.
4. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL (2007) Drugs for bad bugs: Confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6:29–40.
5. Tommasi R, Brown DG, Walkup GK, Manchester JI, Miller AA (2015) ESKAPEing the labyrinth of antibacterial discovery. Nat Rev Drug Discov 14:529–542.
6. Richter MF, et al. (2017) Predictive compound accumulation rules yield a broad-spectrum antibiotic. Nature 545:299–304.
7. Dong J, et al. (2016) Optimal dosing regimen of biapenem in Chinese patients with lower respiratory tract infections based on population pharmacokinetic/ pharmacodynamic modelling and Monte Carlo simulation. Int J Antimicrob Agents 47:202–209.
8. Muller AE, Schmitt-Hoffmann AH, Punt N, Mouton JW (2013) Monte Carlo simulations based on phase 1 studies predict target attainment of ceftobiprole in nosocomial pneumonia patients: A validation study. Antimicrob Agents Chemother 57:2047–2053.
9. Cojutti P, Pai MP, Pea F (2017) Population pharmacokinetics and dosing considerations for the use of linezolid in overweight and obese adult patients. Clin Pharmacokinet 57:989–1000.
10. Stanford Health Care (2017) Stanford Health Care antimicrobial dosing reference guide 2017. Available at https://www.scribd.com/document/368426639/Stanford-Health-Care-Antimicrobial-Dosing-Reference-Guide-2017. Accessed August 1, 2018.
11. Bronson J, Black A, Dhar M, Ellsworth B, Merritt JR (2014) To market, to market-2013. Annu Rep Med Chem 49:437–508.
12. Lorca GL, et al. (2007) Transport capabilities of eleven Gram-positive bacteria: Comparative genomic analyses. Biochim Biophys Acta 1768:1342–1366.
13. Czaplewski L, et al. (2016) Alternatives to antibiotics–A pipeline portfolio review. Lancet Infect Dis 16:239–251.
14. Rappuoli R, Bloom DE, Black S (2017) Deploy vaccines to fight superbugs. Nature 552:165–167.
15. Delany I, Rappuoli R, De Gregorio E (2014) Vaccines for the 21st century. EMBO Mol Med 6:708–720.
16. Delany I, Rappuoli R, Seib KL (2013) Vaccines, reverse vaccinology, and bacterial pathogenesis. Cold Spring Harb Perspect Med 3:a012476.
17. Parikh SR, et al. (2016) Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: A national observational cohort study. Lancet 388:2775–2782.
18. McElhaney JE, et al.; Influence65 study group (2013) AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: A phase 3 randomised trial. Lancet Infect Dis 13:485–496.
19. Vesikari T, et al. (2011) Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 365:1406–1416.
20. Reed SG, Orr MT, Fox CB (2013) Key roles of adjuvants in modern vaccines. Nat Med 19:1597–1608.
21. Otieno L, et al. (2016) Safety and immunogenicity of RTS,S/AS01 malaria vaccine in infants and children with WHO stage 1 or 2 HIV disease: A randomised, double-blind, controlled trial. Lancet Infect Dis 16:1134–1144.
22. Cunningham AL, et al.; ZOE-70 Study Group (2016) Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med 375:1019–1032.
23. Wu TY, et al. (2014) Rational design of small molecules as vaccine adjuvants. Sci Transl Med 6:263ra160.
24. Mancini F, et al. (2016) One dose of Staphylococcus aureus 4C-Staph vaccine formulated with a novel TLR7-dependent adjuvant rapidly protects mice through antibodies, effector CD4+ T cells, and IL-17A. PLoS One 11:e0147767.
25. Rappuoli R, Bottomley MJ, D’Oro U, Finco O, De Gregorio E (2016) Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design. J Exp Med 213:469–481.
26. McLellan JS, et al. (2013) Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342:592–598.
27. Macagno A, et al. (2010) Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol 84:1005–1013.
28. Kanekiyo M, et al. (2013) Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 499:102–106.
29. Ihssen J, et al. (2010) Production of glycoprotein vaccines in Escherichia coli. Microb Cell Fact 9:61.
30. Riddle MS, et al. (2016) Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella flexneri 2a administered to healthy adults: A single-blind, randomized phase I study. Clin Vaccine Immunol 23:908–917.
31. Petousis-Harris H, et al. (2017) Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: A retrospective case-control study. Lancet 390:1603–1610.
32. Gnopo YMD, Watkins HC, Stevenson TC, DeLisa MP, Putnam D (2017) Designer outer membrane vesicles as immunomodulatory systems–Reprogramming bacteria for vaccine delivery. Adv Drug Deliv Rev 114:132–142.
33. Launay O, et al. (2017) Safety profile and immunologic responses of a novel vaccine against Shigella sonnei administered intramuscularly, intradermally and intranasally: Results from two parallel randomized phase 1 clinical studies in healthy adult volunteers in Europe. EBioMedicine 22:164–172.
34. Fairhead H, Wilkinson A, Severi E (2017) US Patent WO 2017/174809, A1.
35. Sahota JS, et al. (2015) Bacteriophage delivery by nebulization and efficacy against phenotypically diverse Pseudomonas aeruginosa from cystic fibrosis patients. J Aerosol Med Pulm Drug Deliv 28:353–360.
36. Nale JY, et al. (2015) Bacteriophage combinations significantly reduce Clostridium difficile growth in vitro and proliferation in vivo. Antimicrob Agents Chemother 60:968–981.
37. Rastogi V, et al. (2018) An overview on bacteriophages: A natural nanostructured antibacterial agent. Curr Drug Deliv 15:3–20.
38. Khanna S, et al. (2016) A novel microbiome therapeutic increases gut microbial diversity and prevents recurrent Clostridium difficile infection. J Infect Dis 214:173–181.
39. Gerding DN, et al. (2015) Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: A randomized clinical trial. JAMA 313:1719–1727.
40. Vedanta Biosciences (2017) Vedanta Biosciences Announces Initiation of Phase 1a/1b Trial for New Drug Class of Rationally-Defined Bacterial Consortia Derived from the Human Microbiome. Available at https://www.vedantabio.com/news-media/press-releases/detail/2298/vedanta-biosciences-announces-initiation-ofphase-1a1b. Accessed August 1, 2018.
41. Pirofski LA, Casadevall A (2006) Immunomodulators as an antimicrobial tool. Curr Opin Microbiol 9:489–495.
42. Smith SB, Magid-Slav M, Brown JR (2013) Host response to respiratory bacterial pathogens as identified by integrated analysis of human gene expression data. PLoS One 8:e75607.
43. Pegu A, Hessell AJ, Mascola JR, Haigwood NL (2017) Use of broadly neutralizing antibodies for HIV-1 prevention. Immunol Rev 275:296–312.
44. DiGiandomenico A, et al. (2014) A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci Transl Med 6:262ra155.
45. Kummerfeldt CE (2014) Raxibacumab: Potential role in the treatment of inhalational anthrax. Infect Drug Resist 7:101–109.
46. Lowy I, et al. (2010) Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 362:197–205.
47. Hey A (2015) History and practice: Antibodies in infectious diseases. Microbiol Spectr 3:AID-0026-2014.
48. Bagnoli F, Payne DJ (2017) Reaction: Alternative modalities to address antibiotic-resistant pathogens. Chem 3:369–372.